MX2022013783A - Compuestos tratanosticos que contienen cobre y metodos de uso. - Google Patents
Compuestos tratanosticos que contienen cobre y metodos de uso.Info
- Publication number
- MX2022013783A MX2022013783A MX2022013783A MX2022013783A MX2022013783A MX 2022013783 A MX2022013783 A MX 2022013783A MX 2022013783 A MX2022013783 A MX 2022013783A MX 2022013783 A MX2022013783 A MX 2022013783A MX 2022013783 A MX2022013783 A MX 2022013783A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- carcinoma
- tumor
- compounds
- domain
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title 1
- 229910052802 copper Inorganic materials 0.000 title 1
- 239000010949 copper Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000004506 Blood Proteins Human genes 0.000 abstract 2
- 108010017384 Blood Proteins Proteins 0.000 abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- NVOVSXGZALWAFS-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane Chemical compound C1NCCNCC2CNCCNCC1CNCCNC2 NVOVSXGZALWAFS-UHFFFAOYSA-N 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000009311 VIPoma Diseases 0.000 abstract 1
- 206010047741 Vulval cancer Diseases 0.000 abstract 1
- 230000001919 adrenal effect Effects 0.000 abstract 1
- 108010070783 alanyltyrosine Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 230000001054 cortical effect Effects 0.000 abstract 1
- 201000003914 endometrial carcinoma Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 201000010175 gallbladder cancer Diseases 0.000 abstract 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 208000037819 metastatic cancer Diseases 0.000 abstract 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 abstract 1
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 208000010916 pituitary tumor Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- -1 such compounds Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 201000004916 vulva carcinoma Diseases 0.000 abstract 1
- 208000013013 vulvar carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente tecnología proporciona compuestos, así como composiciones que incluyen a dichos compuestos, útiles para la obtención de imágenes y/o el tratamiento de un cáncer de pulmón de células no pequeñas, carcinoma de pulmón de células pequeñas, cáncer de vejiga, cáncer de colon, cáncer de vesícula biliar, cáncer pancreático, cáncer de esófago, melanoma, cáncer de hígado, adenocarcinoma gástrico primario, adenocarcinoma colorrectal primario, carcinoma de células renales, cáncer de próstata, un tumor neuroendocrino, un tumor hipofisario, un tumor secretor de péptido intestinal vasoactivo, un glioma, cáncer de mama, un cáncer corticosuprarrenal, un carcinoma cervical, un carcinoma vulvar, un carcinoma endometrial, un carcinoma de ovario primario, un carcinoma de ovario metastásico y/o un cáncer metastásico. Los compuestos incluyen un dominio dirigido a tumor (que incluye un resto capaz de reconocer o interactuar con una diana molecular sobre la superficie de células tumorales), un dominio de unión a proteínas de la sangre y un dominio que contiene sarcofagina, donde el resto del dominio dirigido a tumor está distal a y estéricamente no impedido por el dominio de unión a proteínas de la sangre.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020838P | 2020-05-06 | 2020-05-06 | |
| PCT/US2021/027276 WO2021225760A1 (en) | 2020-05-06 | 2021-04-14 | Copper-containing theragnostic compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013783A true MX2022013783A (es) | 2023-04-19 |
Family
ID=78468268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013783A MX2022013783A (es) | 2020-05-06 | 2021-04-14 | Compuestos tratanosticos que contienen cobre y metodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230165979A1 (es) |
| EP (1) | EP4146236A1 (es) |
| JP (1) | JP2023524977A (es) |
| KR (1) | KR20230027004A (es) |
| CN (1) | CN115989042A (es) |
| AU (1) | AU2021267477A1 (es) |
| CA (1) | CA3178858A1 (es) |
| IL (1) | IL297946A (es) |
| MX (1) | MX2022013783A (es) |
| WO (1) | WO2021225760A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230277697A1 (en) * | 2022-03-03 | 2023-09-07 | Serena Valentini | Theragnostic method for cancer patients |
| WO2024026072A1 (en) | 2022-07-28 | 2024-02-01 | Ratio Therapeutics, Inc. | Fibroblast activation protein-targeted compositions and methods of use thereof |
| US20240189460A1 (en) * | 2022-09-23 | 2024-06-13 | Nuclidium Ag | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014292918A1 (en) * | 2013-07-25 | 2015-11-26 | Sloan-Kettering Institute For Cancer Research | Clinical multimodality-tools for pre-and intraoperative insulinoma diagnostics |
| EP4374924A2 (en) * | 2013-10-18 | 2024-05-29 | Novartis AG | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| KR102484725B1 (ko) * | 2016-11-04 | 2023-01-06 | 클라리티 파마슈티컬스 리미티드 | 방사선 요법 및 진단 영상용 제형 |
| CN110290816B (zh) * | 2016-12-16 | 2022-09-30 | 澳大利亚国立大学 | 用于靶向施用的放射性标记材料 |
| AU2019273132A1 (en) * | 2018-05-23 | 2020-12-17 | Provincial Health Services Authority | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
-
2021
- 2021-04-14 EP EP21799484.7A patent/EP4146236A1/en active Pending
- 2021-04-14 MX MX2022013783A patent/MX2022013783A/es unknown
- 2021-04-14 IL IL297946A patent/IL297946A/en unknown
- 2021-04-14 KR KR1020227041921A patent/KR20230027004A/ko active Search and Examination
- 2021-04-14 AU AU2021267477A patent/AU2021267477A1/en active Pending
- 2021-04-14 CA CA3178858A patent/CA3178858A1/en active Pending
- 2021-04-14 CN CN202180048675.1A patent/CN115989042A/zh active Pending
- 2021-04-14 JP JP2022567270A patent/JP2023524977A/ja active Pending
- 2021-04-14 US US17/922,583 patent/US20230165979A1/en active Pending
- 2021-04-14 WO PCT/US2021/027276 patent/WO2021225760A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3178858A1 (en) | 2021-11-11 |
| WO2021225760A1 (en) | 2021-11-11 |
| EP4146236A1 (en) | 2023-03-15 |
| KR20230027004A (ko) | 2023-02-27 |
| AU2021267477A1 (en) | 2022-12-01 |
| CN115989042A (zh) | 2023-04-18 |
| JP2023524977A (ja) | 2023-06-14 |
| US20230165979A1 (en) | 2023-06-01 |
| IL297946A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013783A (es) | Compuestos tratanosticos que contienen cobre y metodos de uso. | |
| WO2007013894A3 (en) | Phospholipid ether analogs for detecting and treating cancer | |
| PH12019501029A1 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use therefor | |
| Tian et al. | Androgen receptor may be responsible for gender disparity in gastric cancer | |
| CY1120300T1 (el) | Αντισωματα ειδικα στην κλαουδινη 6 (cldn6) | |
| FI3827838T3 (fi) | Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa | |
| NZ515975A (en) | Anti-ErbB antibody-maytansinoid conjugates useful in the treatment of tumors characterised by the overexpression of an ErbB receptor | |
| Gurzu et al. | Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations | |
| NZ596317A (en) | Antibodies directed to her-3 and uses thereof | |
| MX2009012906A (es) | Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer. | |
| WO2005084716A3 (en) | Phospholipid analogs for diagnosis and treatment of cancer | |
| IL266563B (en) | Heterocyclic compounds used as pdk1 inhibitors | |
| WO2006012646A3 (en) | Amacr cancer markers | |
| MX2009011343A (es) | Inhibidores quinasa utiles para el tratamiento de enfermedades mieloproliferativas y otras enfermedades proliferativas. | |
| WO2006015742A3 (de) | Tumormarker zur diagnose von kolorektalen karzinomen und/oder davon abstammender metastasen | |
| MX2023005873A (es) | Tratamiento del cancer. | |
| WO2021226071A3 (en) | Detecting pancreatic neuroendocrine tumors | |
| MX2022013378A (es) | Compuestos novedosos útiles como inhibidores de poli(adp-ribosa) polimerasa (parp). | |
| MX2020004431A (es) | Anticuerpos y metodos de uso. | |
| Sawant et al. | Clinicopathological features and prognostic implications of loss of K5 and gain of K1, K8 and K18 in oral potentially malignant lesions and squamous cell carcinomas: An immunohistochemical analysis | |
| WO2005086638A3 (en) | Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof | |
| NZ595490A (en) | Derivatives of kahalalide F for the treatment of cancer | |
| Zekri et al. | Lymph node ratio may predict relapse free survival and overall survival in patients with stage II & III colorectal carcinoma | |
| WO2003002765A3 (en) | Methods for the diagnosis of cancer based on the obcam and ntm genes | |
| EA202090638A1 (ru) | Антитела и способы применения |